The study’s limitations include the highly selectedstudy population and also the lack of non-NASH controlsor patients with earlier stages of NASH. However,although these data can also be valuable, patients withadvanced NASH are at the most urgent need fortreatment that could improve their clinical and alsopatient-reported outcomes. The source of data, which isclinical trial setting, limits generalizability of our resultsto patients seen in real-world practices. In addition,because all patients had to meet strict inclusion criteriafor clinical trials, NASH patients with significant comorbidities and on certain medications were excluded